Several studies have demonstrated their potential as therapeutic targets and prognostic biomarkers in cancer, with OR51E2, also known as the prostate-specific G-protein-coupled receptor, and OR2B6 showing overexpression in prostate and breast carcinomas, respectively [25,26]. This evidence concerns the gene OR2B6 and breast carcinoma.